OALib Journal期刊
费用：99美元
查看量下载量
WWP1 E3 Ligase Targets LATS1 for Ubiquitin-Mediated Degradation in Breast Cancer Cells
The Large Tumor Suppressor 1 (LATS1) is a serine/threonine kinase and tumor suppressor found down-regulated in various human cancers. LATS1 has recently been identified as a central player of the emerging Hippo signaling pathway, which plays important roles in organ size control, tumorigenesis, and stem cell differentiation and renewal, etc. Although mounting evidence supports a role of LATS1 in tumor suppression and tumorigenesis, how LATS1 is regulated at the molecular level is not fully understood. Recently several positive regulators of LATS1 (Mst1/2, MOB1, Kibra, etc) have been identified but how LATS1 is negatively regulated is still largely unknown. We have recently identified Itch, a member of the NEDD4-like family E3 ubiquitin ligases, as a novel negative regulator of LATS1. However, whether other ubiquitin ligases modulate LATS1 stability and function is unclear. By screening many E3 ligases of the NEDD4-like family using over-expression and short-interference RNA knockdown approaches, we have identified WWP1 E3 ligase as another novel negative regulator of LATS1. We have provided in vitro and in vivo evidence that WWP1 is essential for LATS1 stability and negatively regulate LATS1 by promoting LATS1 degradation through polyubiquitination and the 26S proteasome pathway. Importantly, we also showed that degradation of LATS1 is critical in mediating WWP1-induced increased cell proliferation in breast cancer cells. Since WWP1 is an oncogene and LATS1 is a tumor suppressor gene in breast cancer, our studies provide a promising therapeutic strategy in which developed drugs targeting WWP1 cause activation of LATS1 in suppressing breast cancer cell growth.
References
[]&&Visser S, Yang X (2010) LATS tumor suppressor: A new governor of cellular homeostasis. Cell Cycle 9: .
[]&&Yang X, Yu K, Hao Y, Li DM, Stewart R, et al. (2004) LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nature Cell Biology 6: 609–617.
[]&&Yang X, Li DM, Chen W, Xu T (2001) Human homologue of drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis. Oncogene 20: 6516–23.
[]&&Lai D, Ho KC, Hao Y, Yang X (2011) Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Research 71: .
[]&&Tremblay AM, Camargo FD (2012) Hippo signaling in mammalian stem cells. Seminars in Cell & Developmental Biology 23: 818–826.
[]&&Tapon N, Harvey KF (2012) The hippo pathway-from top to bottom and everything in between. Seminars in Cell & Developmental Biology 23: 768–769.
[]&&Zhao B, Tumaneng K, Guan KL (2011) The hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology 13: 877–883.
[]&&Badouel C, McNeill H (2011) SnapShot: The hippo signaling pathway. Cell 145: 484–484.e1.
[]&&Hao Y, Chun A, Cheung K, Rashidi B, Yang X (2008) Tumor suppressor LATS1 is a negative regulator of oncogene YAP. The Journal of Biological Chemistry 283: .
[]&&Zhao B, Wei X, Li W, Udan RS, Yang Q, et al. (2007) Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development 21: .
[]&&Chan SW, Lim CJ, Guo K, Ng CP, Lee I, et al. (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Research 68: .
[]&&Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, et al. (2008) TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 28: .
[]&&Zhao B, Li L, Guan KL (2010) Hippo signaling at a glance. Journal of Cell Science 123: .
[]&&Xiao L, Chen Y, Ji M, Dong J (2011) KIBRA regulates hippo signaling activity via interactions with large tumor suppressor kinases. The Journal of Biological Chemistry 286: .
[]&&Chow A, Hao Y, Yang X (2010) Molecular characterization of human homologs of yeast MOB1. International Journal of Cancer 126: .
[]&&Ho KC, Zhou Z, She YM, Chun A, Cyr TD, et al. (2011) Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected. Proceedings of the National Academy of Sciences of the United States of America 108: .
[]&&Ingham RJ, Gish G, Pawson T (2004) The Nedd4 family of E3 ubiquitin ligases: Functional diversity within a common modular architecture. Oncogene 23: .
[]&&Zhi X, Chen C (2012) WWP1: A versatile ubiquitin E3 ligase in signaling and diseases. Cellular and Molecular Life Sciences: CMLS 69: .
[]&&Cao X, Xue L, Han L, Ma L, Chen T, et al. (2011) WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) delays cellular senescence by promoting p27(Kip1) degradation in human diploid fibroblasts. The Journal of Biological Chemistry 286: 3.
[]&&Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A (2005) Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. The Journal of Biological Chemistry 280: 2.
[]&&Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, et al. (2004) Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23: .
[]&&Li Y, Zhou Z, Alimandi M, Chen C (2009) WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 28: .
[]&&Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, et al. (2009) Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. International Journal of Cancer 124: .
[]&&Nguyen Huu NS, Ryder WD, Zeps N, Flasza M, Chiu M, et al. (2008) Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. The Journal of Pathology 216: 93–102.
[]&&Chen C, Zhou Z, Ross JS, Zhou W, Dong JT (2007) The amplified WWP1 gene is a potential molecular target in breast cancer. International Journal of Cancer 121: 80–87.
[]&&Chen C, Sun X, Guo P, Dong XY, Sethi P, et al. (2007) Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26: .
[]&&Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: .
[]&&Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779–791.
[]&&Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, et al. (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129–139.
[]&&Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, et al. (2006) The E3 ubiquitin ligase itch controls the protein stability of p63. Proceedings of the National Academy of Sciences of the United States of America 103: 1.
[]&&Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, et al. (2005) The ubiquitin-protein ligase itch regulates p73 stability. The EMBO Journal 24: 836–848.
[]&&Ande SR, Chen J, Maddika S (2009) The ubiquitin pathway: An emerging drug target in cancer therapy. European Journal of Pharmacology 625: 199–205.
[]&&Bernassola F, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: Multiple players in cancer development. Cancer Cell 14: 10–21.
[]&&Chen C, Matesic LE (2007) The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Reviews 26: 587–604.
[]&&Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, et al. (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 11: .
[]&&Ingham RJ, Colwill K, Howard C, Dettwiler S, Lim CS, et al. (2005) WW domains provide a platform for the assembly of multiprotein networks. Molecular and Cellular Biology 25: .
[]&&Sudol M, Harvey KF (2010) Modularity in the hippo signaling pathway. Trends in Biochemical Sciences 35: 627–633.
[]&&Zhang J, Smolen GA, Haber DA (2008) Negative regulation of YAP by LATS1 underscores evolutionary conservation of the drosophila hippo pathway. Cancer Research 68: .
[]&&Love IM, Grossman SR (2012) It takes 15 to tango: Making sense of the many ubiquitin ligases of p53. Genes & Cancer 3: 249–263.
[]&&Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z (1998) Mdm2 association with p53 targets its ubiquitination. Oncogene 17: .
[]&&Wang Z, Yang B, Dong L, Peng B, He X, et al. (2011) A novel oncoprotein Pirh2: Rising from the shadow of MDM2. Cancer Science 102: 909–917.
[]&&Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, et al. (2004) Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. Journal of the National Cancer Institute 96: .
[]&&Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Research 26: .
[]&&Li Y, Zhou Z, Chen C (2008) WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death and Differentiation 15: .
[]&&Oka T, Mazack V, Sudol M (2008) Mst2 and lats kinases regulate apoptotic function of yes kinase-associated protein (YAP). The Journal of Biological Chemistry 283: 2.
Please enable JavaScript to view the
&&&OALib Suggest
Live SupportAsk us anythingThe E3 ubiquitin ligase Itch is required for the differentiation of follicular helper T cells_图文_百度文库
两大类热门资源免费畅读
续费一年阅读会员，立省24元！
The E3 ubiquitin ligase Itch is required for the differentiation of follicular helper T cells
阅读已结束，下载文档到电脑
想免费下载本文？
定制HR最喜欢的简历
下载文档到电脑，方便使用
还剩9页未读，继续阅读
定制HR最喜欢的简历
你可能喜欢